MAP4K4 is a novel MAPK/ERK pathway regulator required for lung adenocarcinoma maintenance
Open Access
- 2 May 2017
- journal article
- research article
- Published by Wiley in Molecular Oncology
- Vol. 11 (6) , 628-639
Abstract
About 76% of patients with lung adenocarcinoma harbor activating mutations in the receptor tyrosine kinase (RTK)/RAS/RAF pathways, leading to aberrant activation of the mitogen-activated protein kinase (MAPK) pathways particularly the MAPK/ERK pathway. However, many lung adenocarcinomas lacking these genomic mutations also display significant MAPK pathway activation, suggesting that additional MAPK pathway alterations remain undetected. This study has identified serine/threonine kinase mitogen-activated protein 4 kinase 4 (MAP4K4) as a novel positive regulator of MAPK/ERK signaling in lung adenocarcinoma. The results showed that MAP4K4 was drastically elevated in lung adenocarcinoma independently of KRAS or EGFR mutation status. Knockdown of MAP4K4 inhibited proliferation, anchorage-independent growth and migration of lung adenocarcinoma cells, and also inhibited human lung adenocarcinoma xenograft growth and metastasis. Mechanistically, we found that MAP4K4 activated ERK through inhibiting protein phosphatase 2 activity. Our results further showed that downregulation of MAP4K4 prevented ERK reactivation in EGFR inhibitor erlotinib-treated lung adenocarcinoma cells. Together, our findings identify MAP4K4 as a novel MAPK/ERK pathway regulator in lung adenocarcinoma that is required for lung adenocarcinoma maintenance.Keywords
Funding Information
- National Cancer Institute (CA166197, CA175202)
- U.S. Public Health Service (CA166197, CA175202)
- National Natural Science Foundation of China (81472697)
- China Scholarship Council (201403170260)
This publication has 33 references indexed in Scilit:
- ATM protein is deficient in over 40% of lung adenocarcinomasOncotarget, 2016
- All roads lead to PP2A: exploiting the therapeutic potential of this phosphataseThe FEBS Journal, 2015
- FAK/PYK2 promotes the Wnt/β-catenin pathway and intestinal tumorigenesis by phosphorylating GSK3βeLife, 2015
- Expression and prognostic significance of MAP4K4 in lung adenocarcinomaPathology - Research and Practice, 2012
- Suppression of PP2A is critical for protection of melanoma cells upon endoplasmic reticulum stressCell Death & Disease, 2012
- A comparison of fixation methods on lung morphology in a murine model of emphysemaAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2010
- Raf-independent, PP2A-dependent MEK activation in response to ERK silencingBiochemical and Biophysical Research Communications, 2009
- The MEK/ERK cascade: From signaling specificity to diverse functionsBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2007
- Tumor Necrosis Factor α (TNFα) Stimulates Map4k4 Expression through TNFα Receptor 1 Signaling to c-Jun and Activating Transcription Factor 2Journal of Biological Chemistry, 2007
- Molecular Characterization of Ste20p, a Potential Mitogen-activated Protein or Extracellular Signal-regulated Kinase Kinase (MEK) Kinase Kinase from Saccharomyces cerevisiaeJournal of Biological Chemistry, 1995